These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16079614)

  • 1. [An examination in comparison Web site with other root on the revised information of drug package insert].
    Okuyama K; Terasawa M; Takahashi T; Yamada Y
    Yakugaku Zasshi; 2005 Aug; 125(8):639-42. PubMed ID: 16079614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Present state and future tasks of "Drug Guide for Patients"].
    Isozaki M
    Yakugaku Zasshi; 2015; 135(2):271-5. PubMed ID: 25747225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Informational content of official pharmaceutical industry web sites about treatments for erectile dysfunction.
    Waack KE; Ernst ME; Graber MA
    Ann Pharmacother; 2004 Dec; 38(12):2029-34. PubMed ID: 15507499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical information in drug package inserts in India.
    Shivkar YM
    J Postgrad Med; 2009; 55(2):104-7. PubMed ID: 19550054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Issues on package inserts of percutaneous tracheostomy kits].
    Mori M; Noguchi T
    Masui; 2007 Sep; 56(9):1104-10. PubMed ID: 17877059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the boxed warnings in package inserts of prescription medicines for medical professionals in Japan.
    Mino Y; Naito T; Ohshiro J; Yamada T; Kawakami J
    Pharm Pract (Granada); 2022; 20(4):2733. PubMed ID: 36793916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between concerns toward adverse reactions during pre-approval drug reviews and the post-approval addition of clinically significant adverse reactions to package inserts: A retrospective analysis of pre-approval drug review reports and safety updates.
    Watanabe K; Murakami M; Masuyama K; Ishiguro C; Matsuda T
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1265-1276. PubMed ID: 30252199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Survey of Description on Package Inserts of OTC Drugs].
    Shimauchi A; Naganuma M; Sasaoka S; Hatahira H; Motooka Y; Hasegawa S; Fukuda A; Nakao S; Sakai C; Yokoyama S; Ino Y; Nakamura M; Iguchi K
    Yakugaku Zasshi; 2018; 138(2):259-267. PubMed ID: 29386439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Improvement of package insert CYP information for prescription drugs marketed in Japan].
    Hirata-Koizumi M; Saito M; Urano T; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):12-8. PubMed ID: 16541745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the Pharmaceuticals and Medical Devices Agency and healthcare professionals in post-marketing safety.
    Mori K; Watanabe M; Horiuchi N; Tamura A; Kutsumi H
    Clin J Gastroenterol; 2014 Apr; 7(2):103-7. PubMed ID: 26183623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of safety-related regulatory actions by Japan's pharmaceutical regulatory agency.
    Ishiguro C; Misu T; Iwasa E; Izawa T
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1314-1320. PubMed ID: 28722235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship Between the Review Time and Various PMDA Consultations in Recent New Drug Approval Cases in Japan.
    Nishiyama K; Toyoshima S; Yamada H; Suzuki H; Nagai N
    Ther Innov Regul Sci; 2018 Nov; 52(6):731-738. PubMed ID: 29714577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does Industry-Conducted All-Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan?
    Suzuki A; Sato H; Sasaki Y
    Clin Transl Sci; 2019 Sep; 12(5):505-512. PubMed ID: 31062933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse-drug-event data provided by pharmaceutical companies.
    Cudny ME; Graham AS
    Am J Health Syst Pharm; 2008 Jun; 65(11):1071-5. PubMed ID: 18499882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the statements in the information on drug metabolizing enzyme in the package insert--the present regulation and its history in Japan, the U.S. and the U.K.
    Watanabe S; Misu T; Kurihara T; Suzuki S; Sakurada T; Satoh N; Ueda S
    Yakushigaku Zasshi; 2008; 43(2):175-80. PubMed ID: 19579828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excessive medical information increase in package inserts.
    Fuchs J; Werner S; Scheunpflug C; Götze EA; Elstermann K; Scheffel K; Domnowski A; Peter G; Hertzsch C; Hippius M
    Int J Clin Pharmacol Ther; 2010 Dec; 48(12):781-90. PubMed ID: 21084033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The Pharmaceuticals and Medical Devices Agency's Approach to Facilitate Risk Communication and Its Challenges].
    Kondo E; Torii M; Oba I; Okamoto M
    Yakugaku Zasshi; 2018; 138(3):307-314. PubMed ID: 29503421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Drives Adoption of National Labels as Global Reference Labels? A Case Study With the JPI.
    Yoshida S; Matsui R; Kikuchi C
    Ther Innov Regul Sci; 2018 Nov; 52(6):724-730. PubMed ID: 29714572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The development and operation of a package inserts service system for electronic medical records].
    Yamada H; Nishimura S; Shimamori Y; Sato S; Hayase Y
    Yakugaku Zasshi; 2003 Mar; 123(3):201-9. PubMed ID: 12693022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in new drug interactions for pharmaceutical products in Japan.
    Yoshida N; Yamada A; Mimura Y; Kawakami J; Adachi I
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):421-7. PubMed ID: 16331581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.